NCT05239650View on ClinicalTrials.gov

Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

July 15, 2022

Primary Completion Date

October 15, 2025

Study Completion Date

October 15, 2026

Conditions

CRC

Interventions

DRUG

HLX07

1000mg

DRUG

HLX10

200mg

DRUG

mFOLFOX6

OXA：85 mg/m2;LV:400 mg/m2；5-FU：400 mg/m2

All Listed Sponsors

lead

Shanghai Henlius Biotech

INDUSTRY